Literature DB >> 16959944

The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.

Maciej J Zamek-Gliszczynski1, Ken-Ichi Nezasa, Xianbin Tian, J Cory Kalvass, Nita J Patel, Thomas J Raub, Kim L R Brouwer.   

Abstract

The role of Mrp2, Bcrp, and P-glycoprotein in the biliary excretion of acetaminophen sulfate (AS) and glucuronide (AG), 4-methylumbelliferyl sulfate (4MUS) and glucuronide (4MUG), and harmol sulfate (HS) and glucuronide (HG) was studied in Abcc2(-/-), Abcg2(-/-), and Abcb1a(-/-)/Abcb1b(-/-) mouse livers perfused with the respective parent compounds using a cassette dosing approach. Biliary clearance of the sulfate conjugates was significantly decreased in Bcrp-deficient mouse livers, resulting in negligible biliary excretion of AS, 4MUS, and HS. It is noteworthy that the most profound decrease in the biliary clearance of the glucuronide conjugates was observed in Bcrp-deficient mouse livers, although the biliary clearance of 4MUG was also approximately 35% lower in Mrp2-deficient mouse livers. As expected, biliary excretion of conjugates was not impaired in P-glycoprotein-deficient livers. An appreciable increase in perfusate recovery due to a shift in the directionality of metabolite excretion, from bile to perfusate, was noted in knockout mice only for conjugates whose biliary clearance constituted an appreciable (> or =37%) fraction of total hepatic excretory clearance (i.e., 4MUS, HG, and HS). Biliary clearance of AG, AS, and 4MUG constituted a small fraction of total hepatic excretory clearance, so an appreciable increase in perfusate recovery of these metabolites was not observed in knockout mice despite markedly decreased biliary excretion. Unlike in rats, where sulfate and glucuronide conjugates were excreted into bile predominantly by Mrp2, mouse Bcrp mediated the biliary excretion of sulfate metabolites and also played a major role in the biliary excretion of the glucuronide metabolites, with some minor contribution from mouse Mrp2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959944     DOI: 10.1124/mol.106.026955

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  30 in total

1.  Relationship between drug/metabolite exposure and impairment of excretory transport function.

Authors:  Maciej J Zamek-Gliszczynski; J Cory Kalvass; Gary M Pollack; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2008-11-20       Impact factor: 3.922

2.  Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan.

Authors:  Aditya G Kohli; Saul Kivimäe; Matthew R Tiffany; Francis C Szoka
Journal:  J Control Release       Date:  2014-05-20       Impact factor: 9.776

3.  Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA.

Authors:  Xing Liu; Vincent H Tam; Ming Hu
Journal:  Mol Pharm       Date:  2007-10-10       Impact factor: 4.939

4.  Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.

Authors:  Yimao Zhang; Youngjoo Byun; Yunzhao R Ren; Jun O Liu; John Laterra; Martin G Pomper
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

Review 5.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

6.  Structural and conformational determinants of macrocycle cell permeability.

Authors:  Björn Over; Pär Matsson; Christian Tyrchan; Per Artursson; Bradley C Doak; Michael A Foley; Constanze Hilgendorf; Stephen E Johnston; Maurice D Lee; Richard J Lewis; Patrick McCarren; Giovanni Muncipinto; Ulf Norinder; Matthew W D Perry; Jeremy R Duvall; Jan Kihlberg
Journal:  Nat Chem Biol       Date:  2016-10-17       Impact factor: 15.040

7.  Breast cancer resistance protein-mediated efflux of luteolin glucuronides in HeLa cells overexpressing UDP-glucuronosyltransferase 1A9.

Authors:  Lan Tang; Ye Li; Wei-Ying Chen; Shan Zeng; Ling-Na Dong; Xiao-Juan Peng; Wen Jiang; Ming Hu; Zhong-Qiu Liu
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

8.  Placental transfer and fetal elimination of morphine-3-beta-glucuronide in the pregnant baboon.

Authors:  Marianne Garland; Kirsten M Abildskov; Tung-Wah Kiu; Salha S Daniel; Piper Weldy; Raymond I Stark
Journal:  Drug Metab Dispos       Date:  2008-06-19       Impact factor: 3.922

9.  The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.

Authors:  Ramola Sane; Shu-Pei Wu; Rong Zhang; James M Gallo
Journal:  Drug Metab Dispos       Date:  2014-01-24       Impact factor: 3.922

10.  Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.

Authors:  Rong Zhao; Thomas J Raub; Geri A Sawada; Steven C Kasper; James A Bacon; Arlene S Bridges; Gary M Pollack
Journal:  Drug Metab Dispos       Date:  2009-03-09       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.